180 related articles for article (PubMed ID: 21070775)
1. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
Conjeevaram HS; Wahed AS; Afdhal N; Howell CD; Everhart JE; Hoofnagle JH;
Gastroenterology; 2011 Feb; 140(2):469-77. PubMed ID: 21070775
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
3. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
[TBL] [Abstract][Full Text] [Related]
7. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
[TBL] [Abstract][Full Text] [Related]
8. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
[TBL] [Abstract][Full Text] [Related]
9. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
[TBL] [Abstract][Full Text] [Related]
12. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
[TBL] [Abstract][Full Text] [Related]
13. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Int J Infect Dis; 2012 Jun; 16(6):e436-41. PubMed ID: 22486858
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
15. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
Fattovich G; Baroni GS; Pasino M; Pierantonelli I; Covolo L; Ieluzzi D; Passigato N; Tonon A; Faraci MG; Guido M; Negro F
Dig Liver Dis; 2012 May; 44(5):419-25. PubMed ID: 22277808
[TBL] [Abstract][Full Text] [Related]
16. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M; Del Mar Viloria M; Andrade RJ; Salmerón J; Diago M; Fernández-Rodríguez CM; Corpas R; Cruz M; Grande L; Vázquez L; Muñoz-De-Rueda P; López-Serrano P; Gila A; Gutiérrez ML; Pérez C; Ruiz-Extremera A; Suárez E; Castillo J
Gastroenterology; 2005 Mar; 128(3):636-41. PubMed ID: 15765399
[TBL] [Abstract][Full Text] [Related]
18. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
Jung HJ; Kim YS; Kim SG; Lee YN; Jeong SW; Jang JY; Lee SH; Kim HS; Kim BS
Clin Mol Hepatol; 2014 Mar; 20(1):38-46. PubMed ID: 24757657
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
